EGFR and neoplasm: To gain a precise insight into distinct sequences of targeted agents, we compared initial cetuximab (arm A) followed by VEGF-targeted therapy with initial bevacizumab (arm B) followed by EGFR-targeted regimens with respect to primary tumor sidedness.